Showing 9341-9350 of 20377 results for "".
- Harnessing Mathematical Models to Unravel Mood Dynamics in Bipolar Disorderhttps://reachmd.com/news/harnessing-mathematical-models-to-unravel-mood-dynamics-in-bipolar-disorder/2484104/A new Springer review shows mathematical modeling of mood dynamics clarifies clinically relevant features of bipolar disorder and holds promise for i
- The Potential Role of Magnesium Supplementation in Depression Managementhttps://reachmd.com/news/the-potential-role-of-magnesium-supplementation-in-depression-management/2475529/Emerging clinical studies, including a systematic review and meta-analysis, suggest that magnesium supplementation may have a modest effect on depressive symptoms, but further research i
- C5aR1: A Critical Biomarker for Metastasis in Cutaneous Squamous Cell Carcinomahttps://reachmd.com/news/c5ar1-a-critical-biomarker-for-metastasis-in-cutaneous-squamous-cell-carcinoma/2474919/Recent identification of complement component 5a receptor 1 (C5aR1) as a critical metastasis biomarker may improve risk stratification and patient management i
- Are Chemical Sunscreens Safe? Dermatologists Reveal What the Science Really Sayshttps://reachmd.com/news/are-chemical-sunscreens-safe-dermatologists-reveal-what-the-science-really-says/2468250/With so many claims flying around TikTok, it's no wonder people are confused — and concerned — about the safety of chemical sunscreens."I just had a patien
- MARINA (AOC 1001): Biomarker Engagement and Safety Signals in DM1https://reachmd.com/news/marina-aoc-1001-biomarker-engagement-and-safety-signals-in-dm1/2485945/Adults with myotonic dystrophy type 1 (DM1) treated with delpacibart etedesiran (AOC 1001) were described in a recent report summarizing phase 1/2 findings from the MARINA program, inc
- Targeting Regulated Cell-Death Pathways in Severe Cutaneous Adverse Reactionshttps://reachmd.com/news/targeting-regulated-cell-death-pathways-in-severe-cutaneous-adverse-reactions/2484242/Investigators have linked formyl peptide receptor 1 (FPR1)–dependent necroptosis to epidermal cell death in SJS/TEN–type reactions and described an FPR1-targeted inhibitor that reduced
- New Horizons in COPD Management: Dupilumab and Ensifentrine Breakthroughshttps://reachmd.com/news/new-horizons-in-copd-management-dupilumab-and-ensifentrine-breakthroughs/2475985/Despite progress in conventional treatments, COPD patients with type 2 inflammation continue to face recurrent exacerbations and unchecked dyspnea, highlighting an urgent need for novel interventions.Although Dupilumab is not yet FDA approved for COPD, the biologics license application for
- Enhancing Diagnostics in Genetic Disorders and Oncology with Quantitative MRIhttps://reachmd.com/news/enhancing-diagnostics-in-genetic-disorders-and-oncology-with-quantitative-mri/2474956/Timely identification of subtle structural changes in conditions such as neurofibromatosis type 1 and uterine cancer remains a critical diagnostic challenge. Quantitative MRI is emerging as a promising tool to help pinpoint these nuances in g
- Pilot Study Suggests Selumetinib's Potential for Cutaneous Neurofibromashttps://reachmd.com/news/pilot-study-suggests-selumetinibs-potential-for-cutaneous-neurofibromas/2471373/A new nonrandomized pilot trial suggested the MEK inhibitor selumetinib was associated with a reduction in the size of cutaneous neurofibromas in patients with Neurofibromatosis Type 1 (NF1). These study, published as a brief rep
- Building Bridges Between Cells for Brain Healthhttps://reachmd.com/news/building-bridges-between-cells-for-brain-health/2467558/The brain contains many cell types, from the prominent neurons to the lesser-known microglia. The latter are integral to the brain’s immune system and play a crucial role as the brain’s cleanup crew. A recent study conducted by researchers from the